1 Ocak 2019 Dergi makalesi Açık Erişim

Yaman, Selma; Cukadar, Nursima; Baran, Furkan; Uyanik, Fatih Burak; Kilinc, Metin; Mert, Tufan

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Yaman, Selma</dc:creator>
  <dc:creator>Cukadar, Nursima</dc:creator>
  <dc:creator>Baran, Furkan</dc:creator>
  <dc:creator>Uyanik, Fatih Burak</dc:creator>
  <dc:creator>Kilinc, Metin</dc:creator>
  <dc:creator>Mert, Tufan</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description>Purpose: This study aimed to investigate the possible antinociceptive, anti-inflammatory and anti-edema effects of systemic (intaperitoneal) and local (intraplantar) bevacizumab in the experimental inflammation model (introduced with Carrageenan).</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/67583</dc:identifier>
  <dc:identifier>oai:zenodo.org:67583</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>CUKUROVA MEDICAL JOURNAL 44 33-40</dc:source>
  <dc:title>Antiangiogenic effect of bevacizumab in monoclonal antibodies in experimental inflammatory pain model</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>